research use only

AZD4547 (Fexagratinib) FGFR inhibitor

Name: AZD4547 (Fexagratinib)
Brand: Selleck Chemicals
SKU: S2801
Rating: 5 (146 reviews)

Cat.No.S2801

Fexagratinib (AZD4547, ABSK 091) is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

Chemical Structure

Molecular Weight: 463.57

Jump to

Quality Control

Batch: Purity: 99.96%

99.96

Related Targets	EGFR VEGFR JAK PDGFR Src HIF FLT FLT3 HER2 Bcr-Abl
Other FGFR Inhibitors	PD173074 BLU9931 Futibatinib (TAS-120) LY2874455 PD-166866 Zoligratinib (Debio-1347) H3B-6527 Fisogatinib (BLU-554) SSR128129E Ferulic Acid

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
SNU449	Growth Inhibition Assay		72 h	IC50=0.082 μM	26351320
SK-HEP-1	Growth Inhibition Assay		72 h	IC50=0.084 μM	26351320
SNU475	Growth Inhibition Assay		72 h	IC50=5.4 μM	26351320
Hep3B	Growth Inhibition Assay		72 h	IC50=6.43 μM	26351320
PLC/PRF5	Growth Inhibition Assay		72 h	IC50=6.55 μM	26351320
Hur7	Growth Inhibition Assay		72 h	IC50=7.25 μM	26351320
HepG2	Growth Inhibition Assay		72 h	IC50=8.73 μM	26351320
SNU449	Clonogenic assay	1 µM	24 h	decreases colony formation significantly	26351320
SK-HEP-1	Clonogenic assay	1 µM	24 h	decreases colony formation significantly	26351320
SNU449	Function Assay	0-2 μM	48 h	causes a decrease of FRS2，AKT, and ERK phosphorylation	26351320
SK-HEP-1	Function Assay	0-2 μM	48 h	causes a decrease of FRS2，AKT, and ERK phosphorylation	26351320
BaF3 FLT3-TEL	Growth Inhibition Assay			GI50=4.6 ± 0.577 μM	26294741
BaF3 RET-TEL	Growth Inhibition Assay			GI50=0.39 ± 0.048 μM	26294741
BaF3 Parental	Growth Inhibition Assay			GI50﹥10 μM	26294741
MOLM14 FLT3/ITD	Growth Inhibition Assay			GI50=0.484 ± 0.157 μM	26294741
MV4-11 FLT3/ITD	Growth Inhibition Assay			GI50=0.459 ± 0.046 μM	26294741
TT RET C634W	Growth Inhibition Assay			GI50=2.9 ± 0.904 μM	26294741
AN3-CA FGFR2 N550K, K310R	Growth Inhibition Assay			GI50=0.031 ± 0.023 μM	26294741
MFE296 FGFR2 N550K	Growth Inhibition Assay			GI50=0.730 ± 0.057 μM	26294741
MFE280 FGFR2 S252W	Growth Inhibition Assay			GI50=0.218 ± 0.073 μM	26294741
Ishikawa FGFF2 over exp.	Growth Inhibition Assay			GI50=4.5 ± 1.51 μM	26294741
HEC1A Normal FGFR2	Growth Inhibition Assay			GI50﹥10 μM	26294741
A549	Cell viability Assay	0.1/1 μM	48 h	enhances Erlotinib induced viability loss	26053020
SGC-7901	Growth Inhibition Assay	1 nM-10 μM	72 h	IC50 of 5-10 μM, inhibits cell viability dose dependently	25576915
HGC-27	Growth Inhibition Assay	1 nM-10 μM	72 h	IC50 of 5-10 μM, inhibits cell viability dose dependently	25576915
MKN-28	Growth Inhibition Assay	1 nM-10 μM	72 h	IC50 of 5-10 μM, inhibits cell viability dose dependently	25576915
NCI-N87	Growth Inhibition Assay	1 nM-10 μM	72 h	IC50 of 5-10 μM, inhibits cell viability dose dependently	25576915
KATOIII	Growth Inhibition Assay	1 nM-10 μM	72 h	IC50 of 10-100 nM, inhibits cell viability dose dependently	25576915
SNU-16	Growth Inhibition Assay	1 nM-10 μM	72 h	IC50 of 10-100 nM, inhibits cell viability dose dependently	25576915
4T1	Growth Inhibition Assay			IC50=0.64±0.11 μM	24642893
MDA-MB-468	Growth Inhibition Assay			IC50=4.9±0.85 μM	24642893
HCT116	Growth Inhibition Assay			IC50=15.9±1.82 μM	24642893
SW620	Growth Inhibition Assay			IC50＞20 μM	24642893
MDA-MB-231	Growth Inhibition Assay			IC50＞20 μM	24642893
CT26	Growth Inhibition Assay			IC50＞20 μM	24642893
SW480	Growth Inhibition Assay			IC50＞20 μM	24642893
4T1	Apoptosis Assay	1.25-20 μM	24 h	induces apoptosis dose dependently	24642893
KG1a	Growth Inhibition Assay			IC50=0.018 μM	22369928
Sum52-PE	Growth Inhibition Assay			IC50=0.041 μM	22369928
KMS11	Growth Inhibition Assay			IC50=0.281 μM	22369928
MCF7	Growth Inhibition Assay			IC50>30 μM	22369928
KG1	Function assay		72 hrs	Inhibition of FGFR1 in human KG1 cells assessed as suppression of cell proliferation after 72 hrs by SRB/CCK-8 assay, IC50 = 0.0002 μM.	27117427
RT112	Function assay		72 hrs	Inhibition of FGFR3 in human RT112 cells assessed as suppression of cell proliferation after 72 hrs by SRB/CCK-8 assay, IC50 = 0.0006 μM.	27117427
KG1	Antiproliferative assay		72 hrs	Antiproliferative activity against human KG1 cells expressing FGFR1 after 72 hrs, IC50 = 0.0019 μM.	29775937
KG1	Antiproliferative assay		72 hrs	Antiproliferative activity against human KG1 cells after 72 hrs by CCK-8 assay, IC50 = 0.0033 μM.	28687204
SNU16	Antiproliferative assay		72 hrs	Antiproliferative activity against human SNU16 cells after 72 hrs by CCK-8 assay, IC50 = 0.0034 μM.	28687204
SNU16	Function assay		72 hrs	Inhibition of recombinant FGFR2 in human SNU16 cells assessed as suppression of cell proliferation after 72 hrs by SRB/CCK-8 assay, IC50 = 0.0036 μM.	27117427
SNU16	Antiproliferative assay		72 hrs	Antiproliferative activity against human SNU16 cells expressing FGFR2 after 72 hrs, IC50 = 0.0062 μM.	29775937
KG1	Antiproliferative assay		72 hrs	Antiproliferative activity against FGFR1-translocated human KG1 cells after 72 hrs by CCK8/MTT assay, IC50 = 0.0064 μM.	27348537
SNU16	Antiproliferative assay		72 hrs	Antiproliferative activity against FGFR2-amplified human SNU16 cells after 72 hrs by CCK8/MTT assay, IC50 = 0.0134 μM.	27348537
KATO III	Function assay		72 hrs	Inhibition of FGFR2 in human KATO III cells assessed as inhibition of cell proliferation after 72 hrs by cell counting kit-8 assay, IC50 = 0.0141 μM.	28714692
KG1	Function assay		72 hrs	Inhibition of FGFR1OP2 fused FGFR1 in human KG1 cells assessed as inhibition of cell proliferation after 72 hrs by cell counting kit-8 assay, IC50 = 0.0161 μM.	28714692
KATO III	Function assay		72 hrs	Inhibition of FGFR2 in human KATO III cells assessed as suppression of cell proliferation after 72 hrs by SRB/CCK-8 assay, IC50 = 0.0202 μM.	27117427
SNU16	Function assay		72 hrs	Inhibition of FGFR2 in human SNU16 cells assessed as inhibition of cell proliferation after 72 hrs by cell counting kit-8 assay, IC50 = 0.0254 μM.	28714692
UM-UC-14	Antiproliferative assay		72 hrs	Antiproliferative activity against human UM-UC-14 cells expressing FGFR3 after 72 hrs, IC50 = 0.0269 μM.	29775937
RT112	Function assay		72 hrs	Inhibition of FGFR3 in human RT112 cells assessed as inhibition of cell proliferation after 72 hrs by cell counting kit-8 assay, IC50 = 0.027 μM.	28714692
UM-UC-14	Function assay		72 hrs	Inhibition of FGFR3 mutant in human UM-UC-14 cells assessed as inhibition of cell proliferation after 72 hrs by cell counting kit-8 assay, IC50 = 0.0271 μM.	28714692
RT112	Antiproliferative assay		72 hrs	Antiproliferative activity against human RT112 cells after 72 hrs by MTT assay, GI50 = 0.0292 μM.	27599742
H1581	Function assay		72 hrs	Inhibition of FGFR1 in human H1581 cells assessed as suppression of cell proliferation after 72 hrs by SRB/CCK-8 assay, IC50 = 0.0329 μM.	27117427
NCI-H1581	Antiproliferative assay		72 hrs	Antiproliferative activity against human NCI-H1581 cells expressing FGFR1 after 72 hrs, IC50 = 0.04 μM.	29775937
B16F10	Cytotoxicity assay		72 hrs	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay, IC50 = 0.051 μM.	25736993
A549	Cytotoxicity assay		72 hrs	Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50 = 0.062 μM.	25736993
NCI-H1581	Function assay		72 hrs	Inhibition of FGFR1 in human NCI-H1581 cells assessed as inhibition of cell proliferation after 72 hrs by cell counting kit-8 assay, IC50 = 0.0626 μM.	28714692
RT112	Antiproliferative assay		72 hrs	Antiproliferative activity against human RT112 cells expressing FGFR3 after 72 hrs, IC50 = 0.0838 μM.	29775937
RT112	Antiproliferative assay		72 hrs	Antiproliferative activity against FGFR3-amplified human RT112 cells after 72 hrs by CCK8/MTT assay, IC50 = 0.0884 μM.	27348537
NCI-H1581	Antiproliferative assay		72 hrs	Antiproliferative activity against FGFR1-amplified human NCI-H1581 cells after 72 hrs by CCK8/MTT assay, IC50 = 0.0921 μM.	27348537
HeLa 229	Cytotoxicity assay		72 hrs	Cytotoxicity against human HeLa 229 cells after 72 hrs by MTT assay, IC50 = 0.14 μM.	25736993
BAF3	Antiproliferative assay		72 hrs	Antiproliferative activity against mouse BAF3 cells expressing VEGFR2 after 72 hrs, IC50 = 0.222 μM.	29775937
SGC7901	Antiproliferative assay		72 hrs	Antiproliferative activity against human SGC7901 cells after 72 hrs by MTT assay, IC50 = 2.8 μM.	27829519
MGC803	Antiproliferative assay		72 hrs	Antiproliferative activity against human MGC803 cells after 72 hrs by MTT assay, IC50 = 6.2 μM.	27829519
BGC823	Antiproliferative assay		72 hrs	Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay, IC50 = 7.9 μM.	27829519
HL7702	Cytotoxicity assay		72 hrs	Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay, IC50 = 18.21 μM.	25736993
U-2 OS	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	29435139
A673	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
Saos-2	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-37	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
SK-N-SH	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
BT-12	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
OHS-50	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
fibroblast cells	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	29435139
Rh41	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
Rh30	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	29435139
SJ-GBM2	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
NB-EBc1	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
LAN-5	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
Rh18	qHTS ssay			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	29435139
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	463.57	Formula	C₂₆H₃₃N₅O₃	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1035270-39-3	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	ABSK 091			Smiles	CC1CN(CC(N1)C)C2=CC=C(C=C2)C(=O)NC3=NNC(=C3)CCC4=CC(=CC(=C4)OC)OC

Solubility

In vitro
Batch:

DMSO : 93 mg/mL (200.61 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 40 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	4%DMSO 1 30%PEG300 2 5%Tween80 3 61%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (10.79mM)	Taking the 1 mL working solution as an example, add 40 μL of 125 mg/ml clarified DMSO stock solution to 300 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 610 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Features	Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.
Targets/IC₅₀/Ki	FGFR1 (Cell-free assay) 0.2 nM FGFR3 (Cell-free assay) 1.8 nM FGFR2 (Cell-free assay) 2.5 nM KDR (Cell-free assay) 24 nM
In vitro	Compared to FGFR1-3, AZD4547 displays weaker activity against FGFR4 with IC50 of 165 nM. AZD4547 only inhibits recombinant VEGFR2 (KDR) kinase activity with IC50 of 24 nM, in the in vitro selectivity test against a diverse panel of representative human kinases. AZD4547 at 0.1 μM exhibits no activity against a range of recombinant kinases including ALK, CHK1, EGFR, MAPK1, MEK1, p70S6K, PDGFR, PKB, Src, Tie2, and PI3-kinase. Consistently, the potent selectivity of AZD4547 for FGFR1-3 over FGFR4, IGFR, and KDR is also observed in cellular phosphorylation assays. AZD4547 has potent in vitro antiproliferative activity only against tumor cell lines expressing deregulated FGFRs such as KG1a, Sum52-PE, and KMS11 with IC50 of 18-281 nM, and is inactive against MCF7 as well as more than 100 additional tumor cell lines. AZD4547 treatment potently inhibits FGFR and MAPK phosphorylation in human tumor cell lines in a dose-dependent manner. AZD4547 also potently inhibits the phosphorylation of FRS2 and PLCγ, downstream markers of FGFR signaling. Notably, AZD4547 affects the AKT phosphorylation in the breast cell lines, MCF7 and Sum52-PE but not in KG1a and KMS11 lines. AZD4547 treatment significantly induces apoptosis in Sum52-PE and KMS11 cells, dramatically increases G1 arrest but not apoptosis in KG1a cells, and has no effect on cell cycle distribution or apoptosis in MCF7 cells.
Kinase Assay	AZD4547 kinase activity
Kinase Assay	The ability of AZD4547 to inhibit the human recombinant kinase activities of FGFR1-3 is tested using ATP concentrations at, or just below, the respective K_m.
In vivo	Oral administration of AZD4547 at 3 mg/kg twice daily in mice bearing KMS11 tumors results in significant tumor growth inhibition of 53% when compared with vehicle-treated controls, and AZD4547 at 12.5 mg/kg once daily or 6.25 mg/kg twice daily leads to complete tumor stasis, which is associated with dose proportional pharmacodynamic modulation of phospho-FGFR3 and reduced KMS11 tumor cell proliferation. Moreover, oral administration of AZD4547 at 12.5 mg/kg once daily results in 65% tumor growth inhibition in the FGFR1-fusion KG1a xenograft model. At efficacious dose levels, AZD4547 does not exhibit antiangiogenic effects. AZD4547 has no significant effect on blood pressure and therefore lacks in vivo anti-KDR activity. Consistently, dosing of 6.25 mg/kg orally twice daily AZD4547 is inactive in the cediranib-sensitive xenograft models including Calu-6, HCT-15 and LoVo.
References	[1] https://pubmed.ncbi.nlm.nih.gov/22369928/

Applications

Methods	Biomarkers	Images	PMID
Western blot	p-FGFR / FGFR1 / p-AKT / AKT / p-ERK / ERK pFRS2		28900173
Growth inhibition assay	Cell viability Cell viability		28900173

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02824133	Completed	Recurrent IDHwt Gliomas With FGFR3-TACC3 Fusion\|Recurrent IDHwt Gliomas With FGFR1-TACC1 Fusion	Assistance Publique - Hôpitaux de Paris	September 2015	Phase 1\|Phase 2
NCT01824901	Completed	Recurrent Non-small Cell Lung Cancer\|Squamous Cell Lung Cancer	ECOG-ACRIN Cancer Research Group\|National Cancer Institute (NCI)\|Eastern Cooperative Oncology Group	January 15 2014	Phase 1\|Phase 2
NCT01795768	Unknown status	Gastric Cancer\|Oesophageal Cancer\|Breast Cancer\|Squamous Cell Carcinoma of the Lung	Royal Marsden NHS Foundation Trust\|AstraZeneca	September 2012	Phase 2
NCT01213160	Completed	Cancer\|Advanced Solid Malignancies	AstraZeneca	November 2010	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):